Advertisement

Topics

With FDA decision near, Novartis bolsters SMA gene therapy case

11:46 EDT 16 Apr 2019 | BioPharmaDive

Zolgensma could be approved by the FDA within weeks. Fresh clinical data give further evidence of the therapy's benefit, although reports of two deaths may invite questions.

Original Article: With FDA decision near, Novartis bolsters SMA gene therapy case

NEXT ARTICLE

More From BioPortfolio on "With FDA decision near, Novartis bolsters SMA gene therapy case"

Advertisement
Quick Search
Advertisement
Advertisement